Shining light on drug discovery: optogenetic screening for TopBP1 biomolecular condensate inhibitors
NAR Cancer · 2025
DOI: 10.1093/narcan/zcaf041 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, 2025. Verfasst von Laura Morano und 13 weiteren Autor:innen. Beteiligte Einrichtung: IGH, Univ Montpellier, CNRS, Montpellier 3436, France. Hauptthemen laut MEDLINE: Drug Discovery, DNA-Binding Proteins, Carrier Proteins, Nuclear Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institut National du Cancer, Agence Nationale de la Recherches, MSDAVENIR.
Abstract (Originalsprache)
Human topoisomerase IIβ binding protein 1 (TopBP1) is a scaffold protein involved in DNA replication initiation, DNA repair, transcription regulation, and checkpoint activation. TopBP1 forms nuclear condensates that act as a molecular switch to amplify ATR activity and promote the activation of the checkpoint effector kinase Chk1. In cancer cells, ATR activity is crucial to tolerate the intrinsically high level of DNA lesions and obstacles that block replication fork progression. Thus, ATR inhibitors are currently tested in clinical trials, often in combination with chemotherapy drugs. However, resistance and toxicity are still major issues. The weak interactions that hold TopBP1 condensates together are highly sensitive to changes in the cellular milieu, suggesting that small molecules may alter the formation of TopBP1 condensates. Here, we developed a high-throughput screening system to identify TopBP1 condensation modulators. This system allowed us to identify FDA-approved drugs, including thimerosal and quinacrine, that inhibit TopBP1 condensation and block the activation of ATR/Chk1 signaling. Mechanistically, quinacrine impaired TopBP1’s ability to associate with chromatin, thereby interfering with its capacity to form condensates. Furthermore, quinacrine enhanced the therapeutic efficacy of 5-fluorouracil and irinotecan, components of the clinically used FOLFIRI regimen in a mouse model of peritoneal carcinomatosis from colorectal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- IGH, Univ Montpellier, CNRS, Montpellier 3436, France.
- Institut de Recherche en Cancérologie de Montpellier, INSERM, CNRS, Univ Montpellier, Montpellier 34298, France.
- Montpellier Ressources Imagerie BioCampus, Univ Montpellier, CNRS, INSERM, Montpellier 34298, France.
ORCID-Profile: Benoît Bordignon, Jihane Basbous
Förderung
- Institut National du Cancer
- Agence Nationale de la Recherches
- MSDAVENIR
Zitieren
APA
Morano, L., Vie, N., Aissanou, A., Hodroj, D., Garambois, V., Fauvre, A., Promonet, A., Egger, T., Bordignon, B., Hassen-Khodja, C., Fiachetti, S., Basbous, J., Gongora, C., & Constantinou, A. (2025). Shining light on drug discovery: optogenetic screening for TopBP1 biomolecular condensate inhibitors. NAR Cancer. https://doi.org/10.1093/narcan/zcaf041
Vancouver
Morano L, Vie N, Aissanou A, Hodroj D, Garambois V, Fauvre A, et al. Shining light on drug discovery: optogenetic screening for TopBP1 biomolecular condensate inhibitors. NAR Cancer. 2025. doi:10.1093/narcan/zcaf041
BibTeX
@article{Morano2025,
author = {Morano, Laura and Vie, Nadia and Aissanou, Adam and Hodroj, Dana and Garambois, Véronique and Fauvre, Alexandra and Promonet, Alexy and Egger, Tom and Bordignon, Benoît and Hassen-Khodja, Cédric and Fiachetti, Solène and Basbous, Jihane and Gongora, Céline and Constantinou, Angelos},
title = {Shining light on drug discovery: optogenetic screening for TopBP1 biomolecular condensate inhibitors},
journal = {NAR Cancer},
year = {2025},
doi = {10.1093/narcan/zcaf041}
}
EUVIMED